论文部分内容阅读
自1976年H_2受体拮抗剂西咪替丁应用于临床后,随之出现的雷尼替丁、法莫替丁和尼扎替丁是消化性溃疡治疗的一次革命。它们疗效肯定,市场巨大。此外,至少还有三种新药,即罗沙替丁(roxatidine)、尼芬替丁(nifentidine)和舒福替丁(sufotidine)正在临床试验中。应用H_2受体拮抗剂最明确的指征是治疗十二指肠和胃溃疡以及返流性食管炎。
Since 1976, H 2 receptor antagonist cimetidine used in clinical, followed by ranitidine, famotidine and nizatidine is a revolution in the treatment of peptic ulcer. They are effective and the market is huge. In addition, at least three new drugs, roxatidine, nifentidine and sufotidine, are in clinical trials. The most clear indication of the use of H 2 receptor antagonists is the treatment of duodenal and gastric ulcers and reflux esophagitis.